Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population.
.
Metabolic or endocrine disease
Known myopathy
Systemic steroid use (> 1 mg/kg hydrocortisone) or exogenous Cushing's syndrome
Psychological, family, sociological or geographical conditions that could potentially limit compliance with the study protocol
History of cancer within the five years prior to the study or Cushing's syndrome due to ACTH-secreting tumor
People with metabolic or endocrine diseases
Cohort
Prospective
GLP-1 Receptor Agonists
DrugParticipants receive GLP-1 RA or GLP-1/GIP dual agonists as part of their standard care for overweight or obesity
Prevalence of sarcopenia / sarcopenic obesity
Myokines levels in serum or plasma
Myokines levels in serum or plasma as measured by ELISA
Myokine expression
Myokine expression in muscle as measured by RT-qPCR or RNA-Seq
Prevalence of MASLD
MASLD as evaluated by Fibroscan, based on controlled attenuation parameter (CAP, in decibels per meter) as a marker of hepatic steatosis
Prevalence of MASH
Prevalence of MASH as evaluated by Fibroscan, based on Liver stiffness measurement (LSM, in kilopascals) as a surrogate of liver fibrosis
Click on the lead sponsor to view all of their trials.
